BEGIN:VCALENDAR VERSION:2.0 PRODID:-//Nuclide//Catalyst calendar//EN CALSCALE:GREGORIAN METHOD:PUBLISH X-WR-CALNAME:Nuclide radiopharmaceutical catalysts X-WR-CALDESC:Regulatory decisions\, expected readouts\, advisory committees \, congresses and deal closings in radiopharmaceuticals\, from nuclide.cc. BEGIN:VEVENT UID:nuclide-catalyst-c-zidesamtinib-pdufa@nuclide.cc DTSTAMP:20261025T131323Z DTSTART;VALUE=DATE:20260918 DTEND;VALUE=DATE:20260919 SUMMARY:FDA decision: zidesamtinib in TKI-pretreated ROS1-positive NSCLC DESCRIPTION:PDUFA target action date stated by Nuvalent when the FDA accept ed the new drug application. Nuvalent's first potential approval.\n\nhttps ://nuclide.cc/catalysts/#c-zidesamtinib-pdufa URL:https://investors.nuvalent.com/news-releases CATEGORIES:Regulatory decision,confirmed TRANSP:TRANSPARENT END:VEVENT BEGIN:VEVENT UID:nuclide-catalyst-c-galleri-pma-decision@nuclide.cc DTSTAMP:20261025T131323Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270102 SUMMARY:Expected 2027: FDA decision on the Galleri multi-cancer early detec tion test (premarket approval) DESCRIPTION:Follows the 23 September 2026 advisory committee. PMA decisions typically come months after the panel\; no date has been announced.\n\nEd itorial estimate\; can slip by quarters.\n\nhttps://nuclide.cc/catalysts/# c-galleri-pma-decision\n\nTiming resolution: year. The event is placed on the first day of the period. URL:https://www.prnewswire.com/news-releases/grail-announces-fda-advisory-c ommittee-meeting-to-review-premarket-approval-application-for-the-galleri- multi-cancer-early-detection-test-302846154.html CATEGORIES:Label or clearance decision,expected TRANSP:TRANSPARENT END:VEVENT BEGIN:VEVENT UID:nuclide-catalyst-c-harmoni-3-readout@nuclide.cc DTSTAMP:20261025T131323Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270102 SUMMARY:Expected 2027: HARMONi-3: ivonescimab plus chemotherapy versus pemb rolizumab plus chemotherapy\, first-line NSCLC DESCRIPTION:The first head-to-head test of the PD-1 x VEGF bispecific again st pembrolizumab in a Western population. Timing is our estimate from the registry record\; the sponsor has not given a date.\n\nEditorial estimate\ ; can slip by quarters.\n\nhttps://nuclide.cc/catalysts/#c-harmoni-3-reado ut\n\nTiming resolution: year. The event is placed on the first day of the period. URL:https://clinicaltrials.gov/study/NCT05899608 CATEGORIES:Expected readout,expected TRANSP:TRANSPARENT END:VEVENT BEGIN:VEVENT UID:nuclide-catalyst-c-sunray-01-readout@nuclide.cc DTSTAMP:20261025T131323Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270102 SUMMARY:Expected 2027: SUNRAY-01: olomorasib plus pembrolizumab\, first-lin e KRAS G12C NSCLC DESCRIPTION:Phase 3 in first-line KRAS G12C-mutant NSCLC. Timing is a regis try-based estimate.\n\nEditorial estimate\; can slip by quarters.\n\nCompa nies: Eli Lilly (incl. Loxo)\n\nhttps://nuclide.cc/catalysts/#c-sunray-01- readout\n\nTiming resolution: year. The event is placed on the first day o f the period. URL:https://clinicaltrials.gov/study/NCT06119581 CATEGORIES:Expected readout,expected TRANSP:TRANSPARENT END:VEVENT BEGIN:VEVENT UID:nuclide-catalyst-c-krascendo-1-readout@nuclide.cc DTSTAMP:20261025T131323Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270102 SUMMARY:Expected 2027: Krascendo 1: divarasib versus sotorasib or adagrasib \, previously treated KRAS G12C NSCLC DESCRIPTION:The first phase 3 comparing KRAS G12C inhibitors head to head. Timing is a registry-based estimate.\n\nEditorial estimate\; can slip by q uarters.\n\nhttps://nuclide.cc/catalysts/#c-krascendo-1-readout\n\nTiming resolution: year. The event is placed on the first day of the period. URL:https://clinicaltrials.gov/study/NCT06497556 CATEGORIES:Expected readout,expected TRANSP:TRANSPARENT END:VEVENT BEGIN:VEVENT UID:nuclide-catalyst-c-ideate-lung02-readout@nuclide.cc DTSTAMP:20261025T131323Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270102 SUMMARY:Expected 2027: IDeate-Lung02: ifinatamab deruxtecan versus chemothe rapy\, relapsed small-cell lung cancer DESCRIPTION:Pivotal phase 3 for the B7-H3 ADC from the Merck and Daiichi Sa nkyo collaboration. Timing is a registry-based estimate.\n\nEditorial esti mate\; can slip by quarters.\n\nCompanies: Merck & Co. (MSD)\n\nhttps://nu clide.cc/catalysts/#c-ideate-lung02-readout\n\nTiming resolution: year. Th e event is placed on the first day of the period. URL:https://clinicaltrials.gov/study/NCT06203210 CATEGORIES:Expected readout,expected TRANSP:TRANSPARENT END:VEVENT BEGIN:VEVENT UID:nuclide-catalyst-c-rejoice-ovarian01-readout@nuclide.cc DTSTAMP:20261025T131323Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270102 SUMMARY:Expected 2027: REJOICE-Ovarian01: raludotatug deruxtecan in platinu m-resistant ovarian cancer DESCRIPTION:Phase 2/3 for the CDH6 ADC. Timing is a registry-based estimate .\n\nEditorial estimate\; can slip by quarters.\n\nCompanies: Merck & Co. (MSD)\n\nhttps://nuclide.cc/catalysts/#c-rejoice-ovarian01-readout\n\nTimi ng resolution: year. The event is placed on the first day of the period. URL:https://clinicaltrials.gov/study/NCT06161025 CATEGORIES:Expected readout,expected TRANSP:TRANSPARENT END:VEVENT BEGIN:VEVENT UID:nuclide-catalyst-c-tropion-lung14-readout@nuclide.cc DTSTAMP:20261025T131323Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270102 SUMMARY:Expected 2027: TROPION-Lung14: datopotamab deruxtecan plus osimerti nib\, first-line EGFR-mutant NSCLC DESCRIPTION:Would move the TROP2 ADC into the first-line EGFR-mutant settin g on top of the standard TKI. Timing is a registry-based estimate.\n\nEdit orial estimate\; can slip by quarters.\n\nCompanies: AstraZeneca\n\nhttps: //nuclide.cc/catalysts/#c-tropion-lung14-readout\n\nTiming resolution: yea r. The event is placed on the first day of the period. URL:https://clinicaltrials.gov/study/NCT06350097 CATEGORIES:Expected readout,expected TRANSP:TRANSPARENT END:VEVENT BEGIN:VEVENT UID:nuclide-catalyst-c-ascent-07-readout@nuclide.cc DTSTAMP:20261025T131323Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270102 SUMMARY:Expected 2027: ASCENT-07: sacituzumab govitecan versus chemotherapy \, first-line HR-positive HER2-negative metastatic breast cancer DESCRIPTION:Tests the ADC as the first chemotherapy after endocrine therapy . Timing is a registry-based estimate.\n\nEditorial estimate\; can slip by quarters.\n\nhttps://nuclide.cc/catalysts/#c-ascent-07-readout\n\nTiming resolution: year. The event is placed on the first day of the period. URL:https://clinicaltrials.gov/study/NCT05840211 CATEGORIES:Expected readout,expected TRANSP:TRANSPARENT END:VEVENT BEGIN:VEVENT UID:nuclide-catalyst-c-intismeran-filing@nuclide.cc DTSTAMP:20261025T131323Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270102 SUMMARY:Expected 2027: Regulatory filings for intismeran autogene plus pemb rolizumab in adjuvant melanoma (INTerpath-001) DESCRIPTION:The sponsors said filings would follow the positive topline res ult of August 2026 and the full data presentation. Timing is our estimate. \n\nEditorial estimate\; can slip by quarters.\n\nCompanies: Merck & Co. ( MSD)\n\nhttps://nuclide.cc/catalysts/#c-intismeran-filing\n\nTiming resolu tion: year. The event is placed on the first day of the period. URL:https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath -001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrenc e-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/ CATEGORIES:Filing,expected TRANSP:TRANSPARENT END:VEVENT BEGIN:VEVENT UID:nuclide-catalyst-c-tempus-personalis-close@nuclide.cc DTSTAMP:20261025T131323Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261002 SUMMARY:Expected Q4 2026: Tempus completes the acquisition of Personalis DESCRIPTION:All-stock deal at $16.25 per share announced July 2026\; the co mpanies guided to a close in late 2026 or early 2027.\n\nEditorial estimat e\; can slip by quarters.\n\nhttps://nuclide.cc/catalysts/#c-tempus-person alis-close\n\nTiming resolution: quarter. The event is placed on the first day of the period. URL:https://investors.tempus.com/news-releases/news-release-details/tempus- acquire-personalis-more-tightly-integrating-molecular CATEGORIES:Deal closing,expected TRANSP:TRANSPARENT END:VEVENT BEGIN:VEVENT UID:nuclide-calendar-cal-0@nuclide.cc DTSTAMP:20261025T131323Z DTSTART;VALUE=DATE:20261017 DTEND;VALUE=DATE:20261018 SUMMARY:EANM'26\, 39th Annual Congress of the European Association of Nucle ar Medicine\, Vienna (17 to 21 October) DESCRIPTION:Europe's largest nuclear medicine congress\, with dedicated rad iopharmacy\, dosimetry and theranostics tracks. European first-in-human ra dioligand data and the EANM guideline updates land here.\n\nhttps://nuclid e.cc/catalysts/#cal-0 URL:https://eanm.org/congress-scientific-events/eanm26/ CATEGORIES:Congress,confirmed TRANSP:TRANSPARENT END:VEVENT BEGIN:VEVENT UID:nuclide-calendar-cal-1@nuclide.cc DTSTAMP:20261025T131323Z DTSTART;VALUE=DATE:20261104 DTEND;VALUE=DATE:20261105 SUMMARY:SNMMI Theranostics Conference 2026\, Bethesda\, Maryland (4 to 7 No vember) DESCRIPTION:SNMMI's conference devoted to theranostics alone: dosimetry pra ctice\, alpha-emitter programmes\, supply and reimbursement rather than br oad nuclear medicine.\n\nhttps://nuclide.cc/catalysts/#cal-1 URL:https://snmmi.org/Theranostics/ CATEGORIES:Congress,confirmed TRANSP:TRANSPARENT END:VEVENT BEGIN:VEVENT UID:nuclide-calendar-cal-2@nuclide.cc DTSTAMP:20261025T131323Z DTSTART;VALUE=DATE:20261106 DTEND;VALUE=DATE:20261107 SUMMARY:65th Annual Meeting of the Korean Society of Nuclear Medicine with the 25th ARCCNM\, Seoul (6 to 7 November) DESCRIPTION:Korea's national nuclear medicine meeting\, held with the Asian Regional Cooperative Council for Nuclear Medicine. Where Korean radioliga nd programmes (FutureChem\, CellBion) report domestically before Western c ongresses.\n\nCompanies: FutureChem\, CellBion\n\nhttps://nuclide.cc/catal ysts/#cal-2 URL:https://www.ksnm.or.kr/eng/ CATEGORIES:Congress,confirmed TRANSP:TRANSPARENT END:VEVENT BEGIN:VEVENT UID:nuclide-calendar-cal-3@nuclide.cc DTSTAMP:20261025T131323Z DTSTART;VALUE=DATE:20261119 DTEND;VALUE=DATE:20261120 SUMMARY:66th Annual Scientific Meeting of the Japanese Society of Nuclear M edicine\, Himeji (19 to 21 November) DESCRIPTION:Japan's national nuclear medicine meeting. Japanese approvals a nd supply questions (domestic Mo-99 production\, PDRadiopharma's product l ine) are discussed here first.\n\nCompanies: PDRadiopharma\, Nihon Medi-Ph ysics\n\nhttps://nuclide.cc/catalysts/#cal-3 URL:https://jsnm.org/english/meetings_and_events/ CATEGORIES:Congress,confirmed TRANSP:TRANSPARENT END:VEVENT BEGIN:VEVENT UID:nuclide-calendar-cal-4@nuclide.cc DTSTAMP:20261025T131323Z DTSTART;VALUE=DATE:20270204 DTEND;VALUE=DATE:20270205 SUMMARY:SNMMI Mid-Winter Meeting 2027\, San Francisco (4 to 6 February) DESCRIPTION:The practice-side SNMMI meeting: radiopharmacy operations\, dos imetry workshops\, regulatory and coding sessions.\n\nhttps://nuclide.cc/c atalysts/#cal-4 URL:https://snmmi.org/AM/Web/Education-and-Meetings/Upcoming-Events.aspx CATEGORIES:Congress,confirmed TRANSP:TRANSPARENT END:VEVENT BEGIN:VEVENT UID:nuclide-calendar-cal-5@nuclide.cc DTSTAMP:20261025T131323Z DTSTART;VALUE=DATE:20270211 DTEND;VALUE=DATE:20270212 SUMMARY:ASCO Genitourinary Cancers Symposium 2027\, San Francisco (11 to 13 February) DESCRIPTION:Where PSMA radioligand therapy trials are first presented. The abstracts are deposited as Journal of Clinical Oncology supplements and ar e harvested by scripts/fetch-abstracts.ts.\n\nCompanies: Novartis\, Lanthe us\, Curium\n\nhttps://nuclide.cc/catalysts/#cal-5 URL:https://www.asco.org/gu CATEGORIES:Congress,confirmed TRANSP:TRANSPARENT END:VEVENT BEGIN:VEVENT UID:nuclide-calendar-cal-6@nuclide.cc DTSTAMP:20261025T131323Z DTSTART;VALUE=DATE:20270311 DTEND;VALUE=DATE:20270312 SUMMARY:9th Theranostics World Congress (TWC2027)\, Osaka (11 to 14 March) DESCRIPTION:Theranostics-only congress with a dedicated targeted alpha ther apy track\; the 2027 edition is in Japan\, which makes it the main meeting point for Asian alpha-emitter programmes.\n\nCompanies: Novartis\, Bayer\ , Fusion Pharmaceuticals (AstraZeneca)\, AstraZeneca\, Orano Med\, RadioMe dix\n\nhttps://nuclide.cc/catalysts/#cal-6 URL:https://www.theranostics-world-congress.org/ CATEGORIES:Congress,confirmed TRANSP:TRANSPARENT END:VEVENT BEGIN:VEVENT UID:nuclide-calendar-cal-7@nuclide.cc DTSTAMP:20261025T131323Z DTSTART;VALUE=DATE:20270430 DTEND;VALUE=DATE:20270501 SUMMARY:57th Annual Scientific Meeting of the Australian and New Zealand So ciety of Nuclear Medicine\, Gold Coast (30 April to 2 May) DESCRIPTION:Australia and New Zealand's nuclear medicine meeting. Australia n developers (Telix\, Clarity) and ANSTO's isotope supply report here.\n\n Companies: ANSTO (Australian Nuclear Science and Technology Organisation)\ , Clarity Pharmaceuticals\, Telix Pharmaceuticals\n\nhttps://nuclide.cc/ca talysts/#cal-7 URL:https://www.anzsnm.org.au/news-events/2027-annual-scientific-meeting/ CATEGORIES:Congress,confirmed TRANSP:TRANSPARENT END:VEVENT BEGIN:VEVENT UID:nuclide-calendar-cal-8@nuclide.cc DTSTAMP:20261025T131323Z DTSTART;VALUE=DATE:20270605 DTEND;VALUE=DATE:20270606 SUMMARY:SNMMI Annual Meeting 2027\, Washington\, DC (5 to 8 June) DESCRIPTION:The largest nuclear medicine meeting in the United States: new tracers\, radiochemistry\, dosimetry and the year's radioligand trial upda tes across oncology\, cardiology and neurology.\n\nhttps://nuclide.cc/cata lysts/#cal-8 URL:https://snmmi.org/AM/Web/Education-and-Meetings/Upcoming-Events.aspx CATEGORIES:Congress,confirmed TRANSP:TRANSPARENT END:VEVENT BEGIN:VEVENT UID:nuclide-calendar-cal-9@nuclide.cc DTSTAMP:20261025T131323Z DTSTART;VALUE=DATE:20271111 DTEND;VALUE=DATE:20271112 SUMMARY:67th Annual Scientific Meeting of the Japanese Society of Nuclear M edicine\, Omiya (11 to 13 November) DESCRIPTION:The 2027 edition of Japan's national nuclear medicine meeting\, announced on the society's English meetings page.\n\nhttps://nuclide.cc/c atalysts/#cal-9 URL:https://jsnm.org/english/meetings_and_events/ CATEGORIES:Congress,confirmed TRANSP:TRANSPARENT END:VEVENT END:VCALENDAR